Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.92 USD | -0.11% | -15.61% | +12.06% |
Apr. 24 | Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge | MT |
Apr. 24 | Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 1,012 | 293.2 | 777.1 | 991.2 | - | - |
Enterprise Value (EV) 1 | 492.9 | -30.6 | 596.3 | 898.2 | 897.6 | 938.3 |
P/E ratio | - | -1.34 x | -5.07 x | -4.9 x | -5.15 x | -6.44 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | 113 x | - | - | 27.2 x |
EV / Revenue | - | - | 87 x | - | - | 25.8 x |
EV / EBITDA | -1.32 x | 0.14 x | -3.5 x | -5.5 x | -4.89 x | -8.47 x |
EV / FCF | - | - | -3.71 x | -5.44 x | -5.31 x | -5.36 x |
FCF Yield | - | - | -26.9% | -18.4% | -18.8% | -18.7% |
Price to Book | 2.06 x | 0.87 x | 3.33 x | 9.01 x | 20.3 x | 24.8 x |
Nbr of stocks (in thousands) | 89,901 | 94,596 | 97,629 | 111,117 | - | - |
Reference price 2 | 11.26 | 3.100 | 7.960 | 8.920 | 8.920 | 8.920 |
Announcement Date | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | 6.853 | - | - | 36.38 |
EBITDA 1 | - | -374 | -212.1 | -170.5 | -163.4 | -183.6 | -110.7 |
EBIT 1 | - | -374.1 | -212.3 | -171.3 | -175.2 | -197.9 | -181.9 |
Operating Margin | - | - | - | -2,499.39% | - | - | -500.12% |
Earnings before Tax (EBT) 1 | - | - | - | -176.1 | -197 | -227.3 | -230.7 |
Net income 1 | -3.149 | - | -216.2 | -151.1 | -195 | -209.5 | -206 |
Net margin | - | - | - | -2,204.65% | - | - | -566.39% |
EPS 2 | -0.4000 | - | -2.310 | -1.570 | -1.820 | -1.732 | -1.385 |
Free Cash Flow 1 | - | - | - | -160.5 | -165 | -169 | -175 |
FCF margin | - | - | - | -2,342.2% | - | - | -481.08% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 4/21/21 | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | 6.853 | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -38.31 | -58.29 | -53.22 | -68.41 | -49.03 | -41.6 | -48.88 | -47.02 | -40.21 | -35.18 | -43.4 | -45.15 | -46.75 | -55 |
Operating Margin | - | - | - | - | - | - | - | - | - | -513.32% | - | - | - | - |
Earnings before Tax (EBT) 1 | - | - | - | - | - | - | - | -48.94 | -41.47 | -35.69 | -44 | -47 | -51 | -55 |
Net income 1 | - | - | - | - | - | -43.17 | -50.71 | -24.89 | -38.65 | -36.84 | -43 | -47 | -49.5 | -55 |
Net margin | - | - | - | - | - | - | - | - | - | -537.53% | - | - | - | - |
EPS 2 | - | - | - | - | - | -0.4500 | -0.5300 | -0.2600 | -0.4000 | -0.3800 | -0.4200 | -0.4467 | -0.4433 | -0.4800 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/15/21 | 3/30/22 | 5/16/22 | 8/10/22 | 11/10/22 | 3/30/23 | 5/12/23 | 8/14/23 | 11/13/23 | 3/28/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | 519 | 324 | 181 | 92.9 | 93.5 | 52.8 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | -161 | -165 | -169 | -175 |
ROE (net income / shareholders' equity) | - | -162% | -52.2% | -52.8% | -95.6% | -234% | -224% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | 5.460 | 3.550 | 2.390 | 0.9900 | 0.4400 | 0.3600 |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 4/21/21 | 3/30/22 | 3/30/23 | 3/28/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.06% | 991M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CNTA Stock
- Financials Centessa Pharmaceuticals plc